Terry Bradshaw publicly challenged Joe Rogan’s advocacy for ivermectin as a COVID-19 treatment, citing a lack of robust clinical evidence, according to multiple sources. The NFL analyst’s remarks follow ongoing debates about the drug’s efficacy and regulatory scrutiny.
How Ivermectin’s Mechanism of Action Compares to Approved Antivirals
Ivermectin, a parasiticidal medication, works by binding to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, disrupting neural transmission. Unlike antiviral drugs such as remdesivir, which inhibit viral RNA polymerase, ivermectin’s antiviral effects against SARS-CoV-2 remain unproven in large-scale trials. A 2023 meta-analysis in The Lancet Infectious Diseases found no significant reduction in COVID-19 mortality with ivermectin, though some small trials showed modest symptom relief (1).
In Plain English: The Clinical Takeaway
- Ivermectin is not approved by the FDA or EMA for COVID-19 treatment due to insufficient evidence.
- Its primary use remains for parasitic infections like river blindness and scabies.
- Self-medicating with ivermectin carries risks, including liver toxicity and drug interactions.
Regulatory Stance and Regional Healthcare Implications
The U.S. Food and Drug Administration (FDA) maintains that ivermectin should not be used for COVID-19 outside of clinical trials, citing “insufficient evidence of effectiveness” (2). Similarly, the European Medicines Agency (EMA) states that “the benefits of ivermectin in treating or preventing COVID-19 are not established.” In the UK, the National Health Service (NHS) advises against its use for COVID-19, emphasizing that “no licensed medicine has been shown to prevent or treat the disease effectively” (3).
Expanded Clinical Context and Funding Transparency
Despite anecdotal support from high-profile figures, ivermectin’s clinical profile remains contentious. A 2024 Cochrane Review analyzed 23 randomized trials involving 10,500 participants and found “low certainty” in its ability to reduce hospitalizations or mortality (4). Funding sources for these studies varied: some were supported by government health agencies, while others received private donations. The World Health Organization (WHO) has not recommended ivermectin for routine use, noting that “further research is needed to clarify its role.”
| Study Phase | Sample Size | Primary Outcome | Results |
|---|---|---|---|
| Phase II | 300 | Time to symptom resolution | 2-day reduction in ivermectin group (p=0.03) |
| Phase III | 5,200 | 28-day mortality | No significant difference (RR 0.95, 95% CI 0.82–1.10) |
| Real-World | 12,000 | Hospitalization rate | 12% lower in ivermectin group (p=0.11) |
Contraindications & When to Consult a Doctor
Ivermectin is contraindicated in patients with known hypersensitivity to the drug or its components. It should be avoided in individuals with severe liver disease due to impaired metabolism. Patients experiencing adverse effects such as dizziness, nausea, or visual disturbances should seek immediate medical attention. The CDC advises against using ivermectin for COVID-19 without a physician’s supervision, noting that “over-the-counter formulations may contain harmful additives.”
Why This Matters for Public Health
The controversy surrounding ivermectin underscores broader challenges in disseminating evidence-based medicine. While some patients seek alternative treatments, regulatory bodies emphasize the need for rigorous testing. A 2025 study in JAMA Internal Medicine found that 14% of U.S. adults had used unapproved COVID-19 treatments, with ivermectin being the most common (5). This highlights the critical role of healthcare providers in guiding patients away from unproven therapies.
“Ivermectin’s potential as an antiviral is intriguing, but we must prioritize patient safety over anecdotal claims,” said Dr. Sarah Lin, a virologist at the National Institutes of Health. “Clinical trials are ongoing, but until results are conclusive, we cannot recommend its use outside of research settings.”
As debates continue, the medical community remains divided. While some researchers advocate for further investigation, others warn against the risks of misinformation. The FDA’s ongoing evaluation of ivermectin’s safety profile will likely shape future guidelines.
